8/7/2020  5:30:19 PM Chg. +0.5400 Volume Bid6:29:49 PM Ask5:40:00 PM Market Capitalization Dividend Y. P/E Ratio
2.2800CHF +31.03% 775,169
Turnover: 1.56 mill.
2.2500Bid Size: 200 2.2900Ask Size: 15,000 74.9 mill.CHF 0.00% -

Business description

Addex Therapeutics (formerly Addex Pharmaceuticals Ltd.) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex' allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline has been generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID. In parallel, dipraglurant's therapeutic use in dystonia is being investigated. Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) program was awarded a $5.3 million grant by the US National Institute on Drug Abuse (NIDA, a division of National Institutes of Health (NIH)) to support human studies in cocaine addiction and has been licensed to Indivior. Discovery programs include mGluR4PAM, mGluR7NAM, mGluR3PAM and TrkBPAM.
 

Management board & Supervisory board

CEO
Tim Dyer
Management board
Jean-Philippe Rocher, Robert Lütjens, Roger G. Mills
Supervisory board
Issac Manke, Jake Nunn, Raymond Hill, Vincent Lawton
 

Company data

Name: Addex Therapeutics Ltd
Address: 12 Chemin des Aulx,CH-1228 Plan-les-Ouates / Genf
Phone: +41-22-884-1555
Fax: +41-22-884-1556
E-mail: info@addextherapeutics.com
Internet: www.addextherapeutics.com
Industry: Healthcare
Sector: Medical Products
Sub sector: Advanced Medical Devices
End of financial year: 12/31
Free Float: 52.72%
IPO date: -

Investor relations

Name: -
IR phone: +41-22-884-1555
IR Fax: -
IR e-mail: investor.relations@a...ics.com investor.relations@addextherapeutics.com

Main Shareholders

Freefloat
 
52.72%
Addex Pharma SA
 
19.01%
Growth Equity Opportunities Fund IV, LLC
 
14.12%
CDK Associates, LLC
 
4.86%
New Leaf Biopharma Opportunities I LP
 
4.86%
CS (CH) Small Cap Switzerland Equity Fund
 
4.43%